Celcuity (CELC) Current Assets (2016 - 2026)
Celcuity's (CELC) quarterly Current Assets came in at $465.7 million in Q4 2025, up 90.4% YoY from $244.6 million in Q4 2024, and down 2.07% on a QoQ basis from $475.5 million in Q3 2025.
Analysis
Celcuity (CELC) Current Assets (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Current Assets data on file, last reported at $465.7 million in Q4 2025.
- Quarterly Current Assets rose 90.4% year-over-year to $465.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $465.7 million (up 90.4% YoY) and the FY2025 annual result came in at $465.7 million, up 90.4% from the prior year.
- Current Assets slipped to $465.7 million in Q4 2025, from $475.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $475.5 million in Q3 2025 to a low of $35.7 million in Q1 2021.
- A 5-year average of $181.7 million and a median of $169.6 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets jumped 601.51% — and 2025, when it plunged 37.28%.
- Tracing CELC's Current Assets over 5 years: stood at $85.4 million in 2021, then soared by 105.26% to $175.2 million in 2022, then grew by 8.79% to $190.6 million in 2023, then grew by 28.32% to $244.6 million in 2024, then surged by 90.4% to $465.7 million in 2025.
- The last three Current Assets figures came in at $465.7 million (Q4 2025), $475.5 million (Q3 2025), and $183.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | 775.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 775.84 Mn |
| Dec 31, 2025 | 465.66 Mn |
| Sep 30, 2025 | 475.50 Mn |
| Jun 30, 2025 | 183.10 Mn |
| Mar 31, 2025 | 217.60 Mn |
| Dec 31, 2024 | 244.57 Mn |
| Sep 30, 2024 | 272.44 Mn |
| Jun 30, 2024 | 291.93 Mn |
| Mar 31, 2024 | 187.52 Mn |
| Dec 31, 2023 | 190.59 Mn |
| Sep 30, 2023 | 141.71 Mn |
| Jun 30, 2023 | 152.81 Mn |
| Mar 31, 2023 | 164.10 Mn |
| Dec 31, 2022 | 175.19 Mn |
| Sep 30, 2022 | 64.69 Mn |
| Jun 30, 2022 | 71.96 Mn |
| Mar 31, 2022 | 79.44 Mn |
| Dec 31, 2021 | 85.35 Mn |
| Sep 30, 2021 | 91.18 Mn |
| Jun 30, 2021 | 42.25 Mn |